ArticleVaccines2026
Assessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015-2025.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesMeasles is a highly contagious infectious disease. Maintaining a high level of measles immunity in the population is essential due to the extremely high transmissibility of the measles virus (MV). We analyzed the MV seroprevalence in the Croatian population.
methodsA total of 1998 individuals tested consecutively for MV antibodies from 2015 to 2025 inclusive were included. MV IgG antibodies were detected using a commercial ELISA.
resultsThe overall seroprevalence rate was 75.1%, with significant yearly differences, ranging from 50.0 to 86.5%, and a declining trend since 2023. No differences were observed between sexes (males 71.6%, females 71.9%). The seroprevalence increased with age, from 60.9% in the 1-10 age group to 91.1% in the 61+ age group. Significant geographic differences were found, with higher seropositivity rates in coastal regions compared to continental regions (81.3 and 71.0%, respectively). Settlement type (urban, suburban/rural) was not associated with the MV seroprevalence. The results of the multivariable logistic regression analysis showed that year, age, and region were significantly associated with IgG seropositivity. Each additional calendar year was associated with lower odds of IgG positivity (OR = 0.82), while each additional year of age was associated with higher odds (OR = 1.04). Region was also a significant predictor (OR = 1.65), while settlement was not significantly associated with seropositivity after adjustment for other variables.
conclusionsCroatia has historically maintained high measles coverage, but lower uptake in some regions and age groups may be creating immunity gaps. The lower post-2022 seropositivity underscores significant immunity gaps, particularly among highly susceptible groups that were exposed to outbreaks and tested during that period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.